This study investigates solid tumors and how often they lose the Human Leukocyte Antigen (HLA) using next generation sequencing. The purpose is to understand HLA loss in these tumors.
The study focuses on collecting and storing participants' T cells for potential future use in CAR T-cell therapy. It evaluates the possibility of using these stored cells to help manage the disease if it relapses.
- Who can participate: Adults with confirmed solid tumors like colorectal, non-small cell lung, pancreatic, mesothelioma, or ovarian cancer that are metastatic or high risk for relapse may join. Participants must have specific HLA typing results and tumor tissue showing HLA loss.
- Study details: Participants will undergo apheresis, a procedure to collect white blood cells. These cells will be stored for possible future CAR T-cell therapy. A placebo is not involved in this study.
- Study timelines: The study will last up to 2 years.
How understandable was the trial content above?
Hard to understand
Easy to understand